Similarly, durable tumor retardation was observed for Panc02 and 4T1 subcutaneous tumor-bearing mice treated with BMDCTEX-N1ND compared with other groups on day 42 (Fig. 2d, e) with similar shifts in circulatory and tumor CD8+ T cells and Tregs (Fig. 2f, g), suggesting that the strategy is broadly applicable across tumor types. This evidence concerns the gene CD8A and neoplasm.